We are live on
!
Find out more
QC
Quadrature Capital Portfolio holdings
AUM
$11.7B
1-Year Est. Return
87.29%
This Fund
S&P 500
This Quarter
Est. Return
+15.89%
1 Year Est. Return
+87.29%
3 Year Est. Return
+211.84%
5 Year Est. Return
+162.22%
10 Year Est. Return
+656.25%
AUM
$8.45B
AUM Growth
+$2.65B
(+46%)
Cap. Flow
+$1.84B
Cap. Flow
% of AUM
21.75%
Top 10 Holdings %
Top 10 Hldgs %
27.48%
Holding
1,605
New
606
Increased
210
Reduced
176
Closed
612
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royal Bank of Canada
RY
|
+$206M |
| 2 |
Toronto Dominion Bank
TD
|
+$181M |
| 3 |
Tesla
TSLA
|
+$177M |
| 4 |
Netflix
NFLX
|
+$173M |
| 5 |
CRWV
CoreWeave
CRWV
|
+$172M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$199M |
| 2 |
UnitedHealth
UNH
|
+$177M |
| 3 |
NVIDIA
NVDA
|
+$111M |
| 4 |
Canadian Imperial Bank of Commerce
CM
|
+$103M |
| 5 |
SoFi Technologies
SOFI
|
+$101M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.44% |
| 2 | Financials | 16.45% |
| 3 | Consumer Discretionary | 10.88% |
| 4 | Industrials | 7.86% |
| 5 | Communication Services | 7.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
926
Candel Therapeutics
CADL
$769M
| $70.5K | ﹤0.01% |
+13,831
| New | +$79.9K |
|
927
Eledon Pharmaceuticals
ELDN
$284M
| $70.3K | ﹤0.01% |
27,100
-1,958
| -7% | -$5.72K |
|
928
MaxCyte
MXCT
$130M
| $70.1K | ﹤0.01% |
44,117
+16,357
| +59% | +$28.4K |
|
929
Microvision
MVIS
$86.9M
| $69.9K | ﹤0.01% |
+3,745
| New | +$66.9K |
|
930
Knightscope
KSCP
$29.2M
| $69.9K | ﹤0.01% |
+12,087
| New | +$74.7K |
|
931
Cerus
CERS
$508M
| $69K | ﹤0.01% |
43,128
+32,131
| +292% | +$43.4K |
|
932
Frontier Group Holdings
ULCC
$1.56B
| $67.5K | ﹤0.01% |
+15,298
| New | +$69.4K |
|
933
Rekor Systems
REKR
$91.2M
| $66.9K | ﹤0.01% |
+42,486
| New | +$53.7K |
|
934
Hain Celestial
HAIN
$53.4M
| $66.8K | ﹤0.01% |
+42,554
| New | +$72.5K |
|
935
Codexis
CDXS
$161M
| $65.6K | ﹤0.01% |
+26,926
| New | +$73.4K |
|
936
Skye Bioscience
SKYE
$18.7M
| $64.8K | ﹤0.01% |
+16,408
| New | +$62K |
|
937
Cardiff Oncology
CRDF
$80.1M
| $64.7K | ﹤0.01% |
31,493
+8,376
| +36% | +$23.1K |
|
|
HUHU
938
HUHUTECH International Group
HUHU
$137M
| $63.9K | ﹤0.01% |
+12,456
| New | +$81.7K |
|
|
BIOA
939
BioAge Labs
BIOA
$526M
| $63.1K | ﹤0.01% |
+10,734
| New | +$50.3K |
|
940
Larimar Therapeutics
LRMR
$417M
| $62.9K | ﹤0.01% |
+19,515
| New | +$73.2K |
|
941
BuzzFeed
BZFD
$94.2M
| $62.1K | ﹤0.01% |
+36,518
| New | +$74.4K |
|
942
Castellum
CTM
$57.8M
| $60.5K | ﹤0.01% |
55,719
+34,630
| +164% | +$40.2K |
|
943
Aclaris Therapeutics
ACRS
$867M
| $59.6K | ﹤0.01% |
31,553
-6,697
| -18% | -$11.7K |
|
944
Fossil Group
FOSL
$317M
| $59.2K | ﹤0.01% |
+23,094
| New | +$54.5K |
|
945
Bioceres Crop Solutions
BIOX
$22.8M
| $59.1K | ﹤0.01% |
+42,196
| New | +$129K |
|
946
Prime Medicine
PRME
$571M
| $56.3K | ﹤0.01% |
+10,182
| New | +$41.4K |
|
947
VistaGen Therapeutics
VTGN
$11.7M
| $55.8K | ﹤0.01% |
+15,752
| New | +$47.1K |
|
948
Pliant Therapeutics
PLRX
$64.4M
| $55.5K | ﹤0.01% |
37,595
-23,626
| -39% | -$36K |
|
949
Conduent
CNDT
$242M
| $55.1K | ﹤0.01% |
+19,655
| New | +$53.2K |
|
950
American Battery Technology Co
ABAT
$361M
| $55K | ﹤0.01% |
+11,338
| New | +$29.6K |
|
Similar funds
BCI
VA
PI
UE
LC
DWM
ERSOT
Quadrature Capital's Q3 2025 Portfolio in Review
As of Q3 2025, Quadrature Capital held 1,605 positions worth $8.45B, up 46% from $5.81B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Quadrature Capital deployed $1.84B of net new capital in Q3 2025, opening 606 new positions and adding to 210 existing holdings. Its largest new stake was Tesla: 510,127 shares worth $227M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $199M trimmed.
- Quadrature Capital's largest Q3 2025 buy was Tesla: 510,127 shares worth $227M.
- Quadrature Capital added most to Royal Bank of Canada in Q3 2025, an estimated $206M increase.
- Quadrature Capital's biggest Q3 2025 reduction was Apple, cutting an estimated $199M.
- Quadrature Capital fully exited UnitedHealth in Q3 2025, selling an estimated $177M.
- Quadrature Capital's ten largest holdings make up 27% of its $8.45B portfolio in Q3 2025.
- Quadrature Capital opened 606 new positions and closed 612 in Q3 2025.
- Quadrature Capital's portfolio value rose 46% quarter-over-quarter to $8.45B.
Based on Quadrature Capital's 13F filing for Q3 2025, filed 13 Nov 2025.